Variation of CYP2C9 Gene and Glycemic Control in Diabetic Patients: A Literature Review
- DOI
- 10.2991/ahsr.k.210115.092How to use a DOI?
- Keywords
- diabetes mellitus type 2, CYP2C9, review
- Abstract
The prevalence of Diabetes Mellitus Type 2 (DMT2) is continuing to increase worldwide. The variety of responses to the oral antidiabetic is influenced by several factors, including genetics, physiology, pathophysiology and the environment. Genetic factors are estimated to contribute 15–30% to differences in metabolism and drug response between individuals. The purpose of this study was to determine the variation of the CYP2C9 gene in DMT2 patients and its association with glycemic control. The method used in this research was literature review. Keywords used for collecting the articles were “CYP2C9, diabetes mellitus, type 2, oral antidiabetic”. Article search was conducted on Google Scholar, PubMed and several international journal providers. The inclusion criteria were articles published in the last 20 years (2000–2020) that addressed the variance and polymorphism of CYP2C9 in DMT2 patients and could be reviewed in full text, including national and international journals. The exclusion criteria in this research were articles that are not original articles. The analysis in this study was performed by describing the qualitative and quantitative results of the journal studies reviewed. We found 13 articles that met the inclusion criteria. The DMT2 patients included in the study were from India, Slovenia, Russia, Mexico, China, Turkey, Egypt, Israel, Greece, Netherlands, Japan, United Kingdom and Germany. Most of the allele variants found were CYP2C9*2 and CYP2C9*3 with heterozygous genotype CYP2C9*1/*2, CYP2C9*1/*3 and heterozygous genotype due to two allele polymorphisms, namely CYP2C9*2/*3. Homozygous genotypes found were CYP2C9*1/*1 (normal genotype) and genotypes due to 2 allele polymorphisms namely CYP2C9*2/*2 and CYP2C9*3/*3. The DMT2 patients with polymorphism experienced better glycemia control than DMT2 patients with the normal genotype. However, those with CYP2C9*2 and CYP2C9*3 polymorphisms experienced higher risk of hypoglycemia. The DMT2 patients mostly have normal CYP2C9*1/*1 genotype, requiring definition of adjustment of dose of oral antidiabetic to obtain the optimal therapeutic effect. However, the hypoglycaemic risk must be closely monitored for DMT2 patients with CYP2C9*2 and CYP2C9*3.
- Copyright
- © 2021, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Nidaul Makwa AU - Dyah A Perwitasari AU - Imaniar N Faridah AU - Lalu M Irham AU - Haafizah Dania AU - Rita Maliza PY - 2021 DA - 2021/01/16 TI - Variation of CYP2C9 Gene and Glycemic Control in Diabetic Patients: A Literature Review BT - Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020) PB - Atlantis Press SP - 466 EP - 474 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.210115.092 DO - 10.2991/ahsr.k.210115.092 ID - Makwa2021 ER -